Fangirling here - Sumbul Desai VP of Health at Apple, previously worked at Disney, now bringing access to health information to the masses with a small metal and glass box that sits on your wrist #MGR @stanforddeptmed.bsky.social

#CCRTP25 cancer immunotherapy session covering the breadth of anti tumor immunity - immune tolerance incited by lymph node involvement @retickerflynn.bsky.social, cytokine conditioning of T cells - A Kalbasi, and synthetic engineering of cytokine receptors - K Daniels @stanford-cancer.bsky.social

Good morning Redwood City 🌞 Rise and shine to Day 2 of the #CCRTP25 @stanford-cancer.bsky.social Still unbelievable to be colleagues with Dr Ron Levy and see how integrated and committed he is to educating the next generation of cancer researchers

Great 💎s on GI cancers at #CCRTP25 @stanford-cancer.bsky.social @corsello.bsky.social -drug discovery w better yield from unexpected hits, then subsequently modified -negative results so important to publish -environmental factors like weight most likely culprits of young onset colon cancer

So far we have talked about non smoking Asian females (lung cancer) and people in their 30s and 40s (colon cancer) and I’m feeling a bit targeted in the worst way 😂 #CCRTP25 @stanford-cancer.bsky.social

The amazing breath of nicotine products today, with significantly higher amounts of nicotine than cigarettes, covered by keynote speaker Carly Kajiwara from the Halpern-Felsher Lab @stanford-cancer.bsky.social #CCRTP25

Good morning Redwood City 🌞 Rise and shine for an action packed day at the Comprehensive Cancer Research Training Program @stanford-cancer.bsky.social - Day 1 of 2 for soaking in cancer research 🤓🥳

@mcuban.bsky.social recently brought his business expertise to #StanDOM's Grand Rounds — diagnosing the American healthcare system & proposing a treatment plan. Watch the full video & read the key takeaways: stanford.io/3FbkfZr

This program reflects our commitment to fostering meaningful partnerships and supporting the next generation of leaders in cancer research. We’re proud to be part of their journey and look forward to the ideas and energy they bring to our community this summer. @funchainmd.bsky.social

Wrapping up #ASCO24 with this thought: let’s get more people under the survival curve and lift it up - it might be prolonged survival, it might even be cure. Every moment counts. May we all walk into our post ASCO lives inspired ✨ 📈 @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma orals #9 ➡️ DANTE trial in 1L metastatic melanoma comparing 1 vs 2 yr anti PD1 + anti CTLA4 ➡️ obstacles to accrual, underpowered, stopping at 1 year non inferior* ➡️ no difference in QOL but less concern with staying on treatment Sarah Danson U Sheffield #ASCO25 @ascocancer.bsky.social

Melanoma orals #8 ➡️ S2000 enco bini nivo vs ipi nivo in symptomatic melanoma brain mets ➡️First randomized trial in symptomatic brain mets ➡️Significant PFS improvement with triple therapy over ipi nivo ➡️No significant OS benefit Zeynep Eroglu, Moffitt #ASCO25 @ascocancer.bsky.social

Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ ➡️ 63.3% for ipi/nivo first ➡️ 33.9% for dab/tram first Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

Melanoma orals #7 ➡️ 5 year overall survival from DREAMSEQ ➡️ 63.3% for ipi/nivo first ➡️ 33.9% for dab/tram first Mike Atkins, Georgetown #ASCO25 @ascocancer.bsky.social

Melanoma orals #6 ➡️ ECOG 6194 ph II pembro + injectable TLR9 agonist vidutolimod in stage III melanoma pCR 71% MPR 79% 1 yr EFS 89% Me: pCR much higher than other studies but with an injectable agent very hard to interpret the systemic effect Ahmad Tarhini #ASCO25 @ascocancer.bsky.social

Melanoma orals #4 ➡️ ph II neoadjuvant dostarlimab + anti TIM3 cobolimab in stage III melanoma D+C with mPR 51.9% with 1 yr EFS 92% Megan Mooradian @mgbresearch.bsky.social #ASCO25 @ascocancer.bsky.social

Melanoma orals #4 ➡️ ph II neadjuvant anti TIGIT tiragolimab and atezolizumab in stage III melanoma ➡️47.7% pCR ➡️91.7% 12 m RFS for those with MPR ➡️no type 1 DM, AI Tina Heiken @mayocliniccancer.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Caroline Robert asks if we should move away from CTCAE grading of irAE in trials and acknowledge the AI (which she notes is more likely focal hypopit rather than AI) is actually a 6% rate of permanent medication-requiring disease #irAE #ASCO25 #melsm @ascocancer.bsky.social @aspire-cop.bsky.social

Discussion of 1st set of melanoma orals by Ana Arance - Toxicities are the *key* challenge in the adjuvant setting and mitigation of #irAE are the priority in this setting #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma orals #3 ➡️ neoadjuvant pembro on stage II/III melanoma Stage IIC SLN positivity significantly different from historical controls; 2 yr RFS “high” Me: Intriguing but hard to understand if true impact given a (moving) historical control Georgios Karakousis #ASCO25 @ascocancer.bsky.social

Melanoma oral #2 #ASCO25 Ph III adjuvant enco bini - Alex van Akkooi summarizes as a tolerable regimen @ascocancer.bsky.social

Melanoma oral #1 #ASCO25 ➡️ ph III adj rela nivo vs nivo (RELATIVITY 098) - no difference in RFS, DMFS Presented by Georgina Long @melanomaau.bsky.social @ascocancer.bsky.social

Actually, yes, this and a fantastic set of encyclopedias

Amazing to meet my fellow ✨Featured Voice✨ Dr @funchainmd.bsky.social at the #WLO event. Best on your presentation today! ‪@aspire-cop.bsky.social‬ #ASPIRE #ASCO25 #HeForShe 💞 #SuppOncSelfies📸 @kmittalmd.bsky.social @ascocancer.bsky.social @oncodaily.bsky.social

Where are TIL today, one year later? #ASCO25 ➡️4 year OS 22.2% ➡️front line with excellent ORR, although 12 month survival lower than checkpoint inhibition ➡️in real practice, multiple paths to, off, and after TIL for individual patients Don Lawrence @mgbresearch.bsky.social @ascocancer.bsky.social

Multiple new agents with mechanisms other than immunotherapies under investigation for metastatic melanoma: ➡️ new BRAF targeting agents ➡️ PRMT5 inhibition ➡️ ROR2 ADC -Meredith McKean, Sarah Cannon #ASCO25 @ascocancer.bsky.social

AI imaging of skin cancer has good prediction but predictive power dropped in a larger pretesting dataset - important to check AI algorithms at multiple time points! Susan Swetter @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social

JAMA Oncology is now on @bsky.app !! Follow @jamaoncology.bsky.social & @jama.com for oncology content #MedSky #OncSky #ASCO25

Much less clarity on whether or not to continue systemic immunotherapy after pCR following neoadjuvant therapy The people have spoken, and they are undedecided - more work to do! #melsm #ASCO25

Ever wonder how pathologists calculate neoadjuvant response metrics (% residual viable tumor, % necrosis, % regression)? Formulas and recommendations for standardized reporting 👇 Janis Taube @hopkinsmedicine.bsky.social #ASCO25 #melsm @ascocancer.bsky.social

Neoadj ipi/nivo is clear winner in melanoma, prompting Genevieve Boland and Diwakar Davar to discuss the CONSTANT communication required between med onc/ surg onc (and relevant subspecialists) perioperatively to address ir-AI or colitis #ASCO25 #irAE @ascocancer.bsky.social @aspire-cop.bsky.social

Melanoma rapid oral #9 ➡️ OBX-115, engineered TIL with membrane bound IL15 regulated with acetazolamide -for 6pt receiving RP2D, 67% ORR, 1 CR, 100% DCR -mDOR not reached Jason Chesney U Louisville and @drbetofmdphd.bsky.social @stanford-cancer.bsky.social #ASCO25 @ascocancer.bsky.social

Melanoma rapid oral #8 ➡️ TIL product characteristics (cell types) that may predict outcome Me: Would be great to access a profile that saves patients from high toxicity profile but honestly would be hard to lose options Lilit Karapetyan @moffittnews.bsky.social #ASCO25 @ascocancer.bsky.social

Rapid melanoma oral #7 ➡️ 5 year outcomes with lifileucel -mDOR 36.5m -31.3% of responders with sustained response -3 pts with PR that deepened after about a year -AEs within first 3 m and drop off dramatically Theresa Medina U Colo #ASCO25 @ascocancer.bsky.social

Melanoma rapid oral #6 ➡️ neoadj lenvatinib + pembro in Merkel cell -57.7% pCR -50% at least 1 TRAE Thoughts - what are we gaining and at what cost? Will be interesting to see long term outcomes given MCC with higher rate of recurrence after CR from IO in stage IV #ASCO25 @ascocancer.bsky.social

Melanoma rapid orals #5 ➡️ single dose of neoadj ipi 3 + nivo 1 with 59% major pathological response and 9% grade 3+ TRAE. CD8 PET not predictive. Sarah Lochrin @mskcc.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Rapid oral #4 adjuvant camrelizumab apatinib and temolozolamide in stage II/MM acral melanoma in a Chinese population with 25% pCR -so impt to understand different biologies by geography/population Lili Mao, Peking U #ASCO25 @ascocancer.bsky.social

Melanoma rapid #3 ➡️ High fiber diet of 30-50g daily is tolerable, pCR 57% in neoadj group, grade 3+ irAE 28.8% Took 400 patients screened to enroll 45 🤔 Yiufan Qiu @mdanderson.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Phase II ipi nivo rela with IL6 inhibitor sarilumab with ORR 68% - highest reported with IO - and grade 3/4 irAEs 12% - lowest reported with combination IO Jan Mehnert @nyulangone.bsky.social #ASCO25 @ascocancer.bsky.social @aspire-cop.bsky.social

Rapid oral #1 - DYP688, novel ADC in mUM, 11/64 pts with response, tolerable, many responses durable Matteo Carlino #ASCO25 @ascocancer.bsky.social

Metastatic mucosal melanoma today: -combination immunotherapy shows lackluster efficacy -MEKi with 25% ORR -KIT + anti PD1 with 54.8% ORR -triplet ICI with 33% ORR -lenv pembro with 50% ORR -TIL with 50% ORR Jun Guo #ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social

Adjuvant and neoadjuvant data for mucosal melanoma summarized by Jun Guo -adjuvant outcomes not as good as cutaneous -neoadjuvant approaches under study #ASCO25 #raremelanoma #rarecancers @ascocancer.bsky.social

Swiftly moving from no options to what to do in what order with so many options - Marlana Orloff, Thomas Jefferson on metastatic uveal melanoma sequencing strategies #ASCO25 @ascocancer.bsky.social

Acral melanoma pearls -adjuvant therapy not effective -targeted therapy with responses (not enough data to clearly choose IO vs targeted as 1L imho) -alternative regimens with efficacy in Asia (different biology than US?) Keri Kendra @ohiostatemed.bsky.social #ASCO25 @ascocancer.bsky.social

Desmoplastic melanoma exquisitely sensitive to PD1 monotherapy, with 3 doses in resectable disease resulting in pCR 57% -Kari Kendra @ohiostatemed.bsky.social #ASCO24 #rarecancers @ascocancer.bsky.social

Alright y’all - last day of #irAE content at #ASCO25 @aspire-cop.bsky.social @ascocancer.bsky.social Monday 6/2 11:30a Bi/Multi-specific Antibodies S406 ➡️Giuseppe Curigliano ➡️Enriquita Felip ➡️Funda Meric Bernstam 3p Beyond Checkpoint E450b ➡️me 😇 ➡️Evan Lipson ➡️Jason Luke

Plenary #1 involves checkpoint inhibition…count with me here 🤔 #ASCO25

So you RCC folks are noticing that combination immunotherapy continues to have durable responses…who knew? 🤔 *melanoma folks nodding in ipi/nivo* 😉 #ASCO25

‼️ Some data suggesting decreased time to progression and decreased survival with cannabis and #immunotherapy. This point deserves a repeat: we do not know the true connections, for the positive or negative, until we test them! #ASCO25

@cliffordhudis.bsky.social at #ASCO25: ~40% cut to NCI budget in Admin's '26 proposal. We are in a tragic paradox: remarkable science & historic cuts to resources needed to turn these opps into hope for millions of pts. Our advocacy, is more important than ever ➡️ brnw.ch/21wT3U4